A partner in the Intellectual Property & Technology Transactions Group, Ian Edvalson is a trusted strategic advisor to biotechnology, pharmaceutical, medical technology and life sciences companies, helping management teams, boards and investors build enterprise value and prepare their most transformational transactions. Ian is ranked by Chambers USA in the Life Sciences: Corporate & Commercial category (2021-2026, 2007-2017).
For over three decades, Ian has partnered with innovative companies at every stage of their lifecycle, from formation and platform creation through commercialization, strategic partnerships and liquidity events. His practice combines deep industry knowledge with practical business judgment to help clients align legal strategy with scientific innovation and long-term commercial objectives.
Clients turn to Ian not simply to negotiate complex agreements, but to help shape business strategy, identify opportunities, manage risk and position their organizations for transformative collaborations, financings, acquisitions and other strategic transactions. Whether advising an emerging biotechnology company developing its first platform technology or executing a multibillion-dollar strategic initiative, Ian focuses on creating durable business relationships and maximizing long-term enterprise value.
Ian regularly advises clients on:
- Strategic collaborations and alliances
- Licensing and partnering strategy
- Mergers, acquisitions and strategic investments
- Corporate spinouts, carve-outs and new company formation
- Roll-up strategies and strategic business combinations
- Strategic business alignments and joint ventures
- Clinical development and commercialization transactions
- Manufacturing, supply and quality agreements
- AI, data, diagnostics and digital health transactions
- Technology development and commercialization
- Board, executive and strategic business counseling
Ian advises clients across the industry, including:
- Biotechnology
- Pharmaceutical
- Cell and gene therapy
- RNA therapeutics
- Precision medicine
- Medical devices
- Diagnostics
- Artificial intelligence
- Digital health
- Health technology
Ian regularly serves as outside strategic counsel to founders, CEOs, boards and investors, helping companies navigate the legal and business decisions that precede, and ultimately shape, their most important strategic transactions.
